PDCD1 and lung carcinoma: The antitumor activity of PD-1 blockade has been confirmed in both animal experiment [38] and clinical trials [39], where the tumor regression in response to PD-1 antibody treatment was observed in refractory solid cancers including colon, renal, and lung cancers and melanoma.